

Healthy Volunteers

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT03222310 GP30057

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03222310 GP30057
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 55 Years

Healthy Volunteers
Accepts Healthy Volunteers
